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haOBJECTIVES This study sought to determine clinical, procedural, and treatment factors associated with acute stent
thrombosis (AST) in the EUROMAX (European Ambulance Acute Coronary Syndrome Angiography) trial.
BACKGROUND Bivalirudin started during transport for primary percutaneous coronary intervention (PCI) for
ST-segment elevation myocardial infarction signiﬁcantly reduced major bleeding compared with heparin with or without
glycoprotein IIb/IIIa inhibitors (GPI), but it was associated with an increase in AST.
METHODS We compared patients with (n ¼ 12) or without AST (n ¼ 2,184) regarding baseline, clinical, and procedural
characteristics and antithrombotic treatment strategies (choice of P2Y12 inhibitor, post–primary PCI bivalirudin infusion
dose [0.25 mg/kg/h, or BIV-LOW] vs. [1.75 mg/kg/h, or BIV-PCI] vs. heparin  GPI). Logistic regression was performed to
identify independent correlates of AST.
RESULTS The overall AST rate was 0.6% and was higher with bivalirudin than with heparin  GPI (1.1% vs. 0.2%;
p ¼ 0.007). Median time to AST was 2.3 h (interquartile range: 1.9 to 2.8 h). Patients with AST had less hypertension
(2 of 14 [14.0%] vs. 961 of 2,182 [44.0%]; p ¼ 0.03), and more frequently received GPI (11 of 14 [78.6%] vs. 880 of
2,183 [40.3%]; p ¼ 0.004). Multivariate analysis using Firth penalized maximum likelihood estimation found hyper-
tension (odds ratio [OR]: 0.24, 95% conﬁdence interval [CI]: 0.07 to 0.92; p ¼ 0.037) and BIV-LOW (OR: 5.8, 95% CI: 1.5
to 22.2; p ¼ 0.010) predictive of AST. Choice of P2Y12 inhibitor had no impact on AST. Compared with heparin  GPI, AST
rates were higher for BIV-LOW (11 of 670 [1.6%] vs. 2 of 947 [0.2%]; p ¼ 0.008), but not different for BIV-PCI (1 of 244
[0.4%]; p ¼ 0.588).
CONCLUSIONS In this post-hoc analysis from EUROMAX, AST occurred very early and was not mitigated by the novel
P2Y12 inhibitors. Prolonging the bivalirudin infusion at the PCI dose (but not at a lower dose) appeared to mitigate the risk
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AND ACRONYM S
AST = acute stent thrombosis
BIV-LOW = reduced dose of
bivalirudin
BIV-PCI = full dose of
bivalirudin
CABG = coronary artery bypass
graft
GPI = glycoprotein inhibitor
IDR = ischemia-driven
revascularization
OR = odds ratio
PCI = percutaneous coronary
intervention
pPCI = primary percutaneous
coronary intervention
ST = stent thrombosis
STEMI = ST-segment elevation
myocardial infarction
TIMI = Thrombolysis InP rimary percutaneous coronary intervention(pPCI) with stent implantation is recognizedas the treatment of choice for most patients
with evolving ST-segment elevation myocardial
infarction (STEMI). In these patients, an increased
risk of early stent thrombosis (ST) has been
noted compared with patients with stable disease
and a large number of patient-related, lesion-related,
procedural, and post-procedural factors have been
associatedwith ST, including type of stent, lesion char-
acteristics, and thrombus burden (1–5). The choice
of antithrombotic therapy in pPCI is an additional
important determinant of clinical outcomes, including
rates of ST. In the HORIZONS-AMI (Harmonizing Out-
comes with Revascularization and Stents in Acute
Myocardial Infarction) trial, the largest pPCI trial to
date, compared with unfractionated heparin and
glycoprotein IIb/IIIa inhibitors (GPI), bivalirudin
reduced rates of net adverse clinical events, major
bleeding, and death at 30 days with a survival beneﬁt
that extended to 3 years (6,7). However, an absoluteSEE PAGE 221
Myocardial Infarction1% excess of acute stent thrombosis (AST) was
observed in the bivalirudin arm with the difference in
ST rates between treatments no longer present at 30
days (1). Since theHORIZONS-AMI trial was conducted,
pPCI practice has evolved with increasing rates of pre-
hospital diagnosis and initiation of treatment (8,9), use
of radial access for catheterization (10–12), and use of
the novel oral P2Y12 inhibitors ticagrelor and prasu-
grel, whereas routine use of GPI has been on the
decline (13–17). The EUROMAX (European Ambu-
lance Acute Coronary Syndrome Angiography) trial
was designed to test whether bivalirudin, initiated
during transport for pPCI in STEMI patients, was su-
perior to the use of heparin-based anticoagulation in
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EUROMAX demonstrated a signiﬁcant
decrease in the primary endpoint of death
and major bleeding with bivalirudin, but
also showed the same 1% absolute increase
in AST when compared with use of heparin
with optional GPI, despite the use of an
extended, albeit primarily low dose, bivalir-
udin infusion for up to 4 h after pPCI (8).
The aims of the present analysis were to
determine whether clinical, procedural, or
antithrombotic treatment-related factors,
such as the choice of dose for the prolonged
bivalirudin infusion, were associated with
AST in the EUROMAX trial.
METHODS
EUROMAX randomized 2,198 patients trans-
ported for pPCI following a presumed diag-
nosis of STEMI (8). The details of the
EUROMAX study design have been previ-
ously published (18). In brief, all patients had to be
scheduled for angiography with the intention of per-
forming pPCI within 2 h after ﬁrst medical contact.
The main exclusion criteria were treatment with any
anticoagulant before randomization, recent surgery,
and a history of bleeding. Patients were identiﬁed,
initial consent was obtained, randomization was
performed, and study drug administration was initi-
ated in the ambulance or in a non-PCI-capable hos-
pital. Patients were transported urgently to the pPCI
hospital, where treatment was continued and out-
comes data collected. All patients initially provided
full or abridged written or oral informed consent
in the ambulance or non-PCI hospital according
to local ethical rules. This consent was subsequently
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216consent during hospitalization. The study was
approved by both local ethics committees and
national health authorities (18).
TREATMENT. The patients were randomized to
treatment with either bivalirudin or heparin (unfrac-
tionated or low-molecular-weight heparin) with or
without a GPI. Patients who were assigned to the
bivalirudin group received a bolus of 0.75 mg/kg of
body weight, followed by an infusion of bivalirudin of
1.75 mg/kg/h. The protocol speciﬁed that the bivalir-
udin infusion should be continued for 4 h after pPCI
at the reduced dose of 0.25 mg/kg/h (BIV-LOW); the
option to prolong the infusion at the full PCI dose of
1.75 mg/kg/h (BIV-PCI) for up to 4 h was also allowed.
Bailout use of GPI in the bivalirudin arm was allowed
in the event of massive thrombus burden or micro-
vascular obstruction (no reﬂow). Patients who were
assigned to the heparin arm (control group) received
either unfractionated heparin (100 IU/kg without a
GPI or 60 IU/kg with a GPI) or an intravenous bolus of
enoxaparin (0.5 mg/kg). The use of GPI was left to the
physician’s preference and was categorized as either
“routine” when started before the index procedure
(emergent angiography  PCI) or “bailout” when
started during or after the procedure for the man-
agement of large thrombus burden or no reﬂow. Any
GPI could be used at the approved doses and regi-
mens. All patients received aspirin and a loading dose
of an approved P2Y12 inhibitor as early as possible
after ﬁrst medical contact. Decisions regarding access
site, performance of thrombus aspiration, and stent
type were left to the physician’s discretion (8).
STATISTICAL ANALYSIS. Baseline, clinical, and pro-
cedural characteristics and treatment strategies were
compared between patients with or without AST
using the chi-square test and the Wilcoxon signed
rank nonparametric test. Comparison of outcomes
between the treatment arms was done using the chi-
square test and the log-rank test. Logistic regression
using Firth penalized maximum likelihood estimation
was performed to determine independent predictors
of AST. The initial list of candidate variables in-
cluded the following: age >65 years, sex, anemia,
renal function, diabetes, hypertension, hyperlipid-
emia, smoker, previous PCI, myocardial infarction,
or coronary artery bypass graft (CABG) surgery;
choice of P2Y12 inhibition (clopidogrel vs. newer
agents); occurrence of procedural complications; pre-
PCI TIMI (Thrombolysis In Myocardial Infarction) ﬂow
grade (0/1 vs. 2/3); single- or multivessel disease;
Killip class II to IV versus class I; access site (femoral
vs. radial); drug-eluting stents; and anticoagulant
strategy: BIV-LOW versus heparin plus optional GPIor BIV-PCI versus heparin plus optional GPI. From the
initial list of 19 variables, only 3 (age >65 years,
hypertension, and BIV-LOW) were found to be sig-
niﬁcant and only hypertension and BIV-LOW were
signiﬁcant in the ﬁnal model.
STUDY OUTCOMES. The primary endpoint of the
EUROMAX trial was a composite of death and non-
CABG-related protocol-deﬁned major bleeding at
30 days. The key secondary endpoint was the com-
posite of death, reinfarction, or non-CABG major
bleeding. Additional pre-speciﬁed secondary end-
points included the following: major adverse cardiac
events (death, reinfarction, ischemia-driven revas-
cularization [IDR], or stroke); net adverse clinical
events (death, reinfarction, IDR, stroke, or non-CABG
major bleeding); each of the components of the pri-
mary and secondary composite endpoints; IDR; ST
(as deﬁned by the Academic Research Consortium
(19)); and a composite of reinfarction, IDR, or ST.
The protocol deﬁnition of non-CABG major
bleeding has been previously published (18). Bleeding
events were also classiﬁed using TIMI and GUSTO
(Global Utilization of Streptokinase and Tissue Plas-
minogen Activator for Occluded Coronary Arteries)
criteria (20,21).
All deaths, bleeding episodes, reinfarction, IDR,
ST, and strokes were adjudicated by a blinded clinical
events committee.
The primary outcome for the present analysis was
the occurrence of Academic Research Consortium–
deﬁned AST (i.e., ST occurring within 24 h after pPCI).RESULTS
Among 2,218 patients enrolled in the trial, 2,198 pro-
vided full informed consent and were included in the
intention-to-treat population, which comprised the
population for the present analysis. The 2,198 pa-
tients were randomized to treatment with either
bivalirudin (n ¼ 1,089) or heparin  GPI (n ¼ 1,109).
The overall rate of AST was 0.6% (n ¼ 14) and the
baseline characteristics of patients with and without
AST is presented in Table 1. Patients with AST pre-
sented with numerically fewer risk factors despite
older age. Patients with AST versus those without AST
had less hypertension (14.0% vs. 44.0%; p ¼ 0.03).
Procedural characteristics and concomitant anti-
platelet therapy from the pre-hospital phase through
discharge are shown in Table 2. Patients with AST
more often had procedural complications (21.4% vs.
6.6%; p ¼ 0.03) and numerically more right coronary
artery interventions (64.3% vs. 43.7%; p ¼ 0.12). Pa-
tients with AST were also more likely to have received
TABLE 2 Procedural Characteristics and Treatments
Acute ST
(n ¼ 14)
No Acute ST
(n ¼ 2,184) p Value
Single-vessel disease 6 (42.9) 1,141/2,138 (53.4) 0.51
PCI done 14 (100.0) 1,875/2,184 (85.9) 0.13
Left anterior
descending artery
5 (35.7) 843/1,875 (45.0) 0.49
Left circumﬂex
coronary artery
0 (0.0) 247/1,875 (13.2) 0.15
Right coronary artery 9 (64.3) 820/1,875 (43.7) 0.12
Balloon angioplasty only 0 (0.0) 90/1,875 (4.8) 0.40
Stent implanted 14 (100.0) 1,719/1,875 (91.7) 0.26
Drug-eluting stent 7 (50.0) 1,060/1,875 (56.5) 0.62
Thrombectomy 5 (35.7) 597/1,875 (31.8) 0.76
Procedural complication 3 (21.4) 123/1,875 (6.6) 0.03
Pre-PCI TIMI ﬂow grade
0/1 7/13 (53.8) 1,149/1,850 (62.1) 0.72*
2 3/13 (23.1) 298/1,850 (16.1)
3 3/13 (23.1) 403/1,850 (21.8)
Post-PCI TIMI ﬂow grade
0/1 0/13 (0.0) 34/1,849 (1.8) 0.87*
2 0/13 (0.0) 60/1,849 (3.2)
3 13/13 (100.0) 1,755/1,849 (94.9)
Aspirin use 14 (100.0) 2,181/2,183 (99.9) 0.91
P2Y12 inhibitor loading
dose (overall)
13 (100.0) 2,093/2,136 (98.0) 0.61
Clopidogrel 5/13 (38.5) 1,064/2,091 (50.9) 0.05*
Prasugrel 2/13 (15.4) 627/2,091 (30.0)
Ticagrelor 6/13 (46.2) 400/2,091 (19.1)
Glycoprotein IIb/IIIa
inhibitor use
11/14 (78.6) 880/2,183 (40.3) 0.004
Routine 3/11 (27.3) 688/880 (78.2) <0.001*
Bailout 8/11 (72.7) 192/880 (21.8)
Values are n (%) or n/N (%). *These p values represent intracategory differences.
TIMI ¼ Thrombolysis In Myocardial Infarction; other abbreviations as in Table 1.
TABLE 1 Baseline Characteristics
Acute ST
(n ¼ 14)
No Acute ST
(n ¼ 2,184) p Value
Age (yrs) median (IQR) 63 (54, 72) 61 (62, 71) 0.50
Age >65 yrs 6 (42.9) 822 (37.6) 0.69
Female 5 (35.7) 518 (23.7) 0.29
Diabetes 1 (7.1) 295 (13.5) 0.49
Hypertension 2 (14.3) 961 (44.0) 0.03
Hyperlipidemia 3 (21.4) 812 (37.2) 0.22
Current smoker 3 (21.4) 922 (42.3) 0.13
Previous myocardial infarction 0 (0.0) 193 (8.8) 0.24
Previous PCI 0 (0.0) 205 (9.4) 0.22
Previous CABG 0 (0.0) 47 (2.2) 0.58
Killip class II–IV 1 (7.7) 145 (7.3) 0.96
Anemia 0 (0.0) 277 (14.1) 0.14
Creatinine clearance
#60 ml/min 0 (0.0) 312 (15.7) 0.27*
>60 ml/min 14 (100.0) 1,673 (84.3)
Values are n (%). *This p value represents intracategory differences.
CABG ¼ coronary artery bypass graft; IQR ¼ interquartile range; PCI ¼ percuta-
neous coronary intervention; ST ¼ stent thrombosis.
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217GPI (78.6% vs. 40.3%; p ¼ 0.004). Of note is that in
patients with AST in the heparin group (n ¼ 2) GPI
administration was routine rather than bailout.
The rate of AST was higher with bivalirudin than
with heparin  GPI (1.1% vs. 0.2%; p ¼ 0.007). Cases
of AST were clustered in the ﬁrst few hours after
pPCI with a median time of occurrence of just 2.3 h
(interquartile range: 1.9 to 2.8 h) from the start of
angiography (Figure 1). None of the AST cases were
fatal. Of the 12 patients with AST who received
bivalirudin, 11 received BIV-LOW and 1 received BIV-
PCI. In the multivariate analysis using Firth penal-
ized maximum likelihood estimation hypertension
(odds ratio [OR]: 0.24, p ¼ 0.037) and receipt of BIV-
LOW (OR: 5.8, p ¼ 0.010) were predictors of AST. The
rate of AST in BIV-LOW was signiﬁcantly higher than
with heparin  GPI (11 of 670 [1.6%] vs. 2 of 947
[0.2%]; p ¼ 0.008), whereas the AST rate in patients
who received BIV-PCI was comparable to that for
patients treated with heparin  GPI. Table 3 provides
outcomes according to anticoagulant strategy and
post-PCI bivalirudin infusion dose. Of the patients
randomized to bivalirudin who underwent pPCI,
73.3% (670 of 914) received the BIV-LOW infusion
after the PCI at 0.25 mg/kg/h (median duration 240
min), and 26.7% (244 of 914) continued the infusion
at the PCI dose (total median duration of 240 min
from the start of PCI). The bleeding risk was not
increased among the patients in the BIV-PCI group
compared with those in the BIV-LOW group (2.9% vs.
2.4%) and bleeding rates were lower than thatobserved in the heparin  GPI treated group (6%).
Reasons for continuing with the BIV-PCI dose were
not collected. There were differences in clinical
characteristics between patients who received BIV-
LOW and BIV-PCI for the extended infusion. Among
the latter, there were more smokers, more hyperlip-
idemia, hypertension, and left main disease, fewer
patients treated with P2Y12 inhibitors before angiog-
raphy, more bailout GPI use, less thrombectomy,
fewer patients with post-PCI TIMI ﬂow, and higher
incidence of failed procedures. Overall patient and
procedural risk appeared to be higher in the BIV-PCI
group, which may in turn have been the determinant
for the choice of the higher dose for the prolonged
infusion. Accordingly, clinical outcomes in the BIV-
PCI group may also have been a reﬂection of their
clinical and procedural proﬁle.
The cumulative incidence of ST events in the ﬁrst
24 h and in the ﬁrst 30 days are shown in Figures 1A
and 1B, respectively.
FIGURE 1 Acute Stent Thrombosis
Cumulative incidence rates of ﬁrst occurrence of stent thrombosis in the ﬁrst 24 h (A) and the ﬁrst 30 days (B) from study drug initiation.
AST ¼ acute stent thrombosis; GPI ¼ glycoprotein IIb/IIIa inhibitors; IQR ¼ interquartile range.
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218The choice of oral P2Y12 inhibitor (clopidogrel
vs. prasugrel or ticagrelor) did not appear to affect
the rates of 30-day ST or AST. Speciﬁcally, AST
rates among patients receiving prasugrel or tica-
grelor was 0.8% (8 of 1,035) versus 0.5% (5 of
1,069) in patients receiving clopidogrel. The overall
30-day rate of deﬁnite ST was 1.1% (13 of 1,135)
among patients receiving the new oral P2Y12 in-
hibitors and 1.0% (8 of 784) in patients receiving
clopidogrel.DISCUSSION
In the EUROMAX trial, the overall incidence of AST
was low (0.6%), but the risk was higher among pa-
tients randomized to bivalirudin. This is in keeping
with similar observations from HORIZONS-AMI.
Although the absolute number of AST cases was
small, thereby precluding the deﬁnitive assessment
of associated factors, EUROMAX provided additional
information on AST in the setting of contemporary
TABLE 3 Comparison of Outcomes by Randomized Treatment Group and Bivalirudin Post-PCI Infusion Dose*
Heparin  GPI
(n ¼ 947)
Bivalirudin Prolonged at Low Dose Bivalirudin Prolonged at PCI Dose
(n ¼ 670) RR (95% CI)† p Value† (n ¼ 244) RR (95% CI)‡ p Value‡
Primary outcome—death or
non-CABG major bleeding
76 (8.0) 22 (3.3) 0.41 (0.26–0.65) 0.0002 18 (7.4) 0.92 (0.56–1.51) 0.738
Key secondary outcome—death, reinfarction,
or non-CABG major bleed
84 (8.9) 36 (5.4) 0.61 (0.42–0.88) 0.009 20 (8.2) 0.92 (0.58–1.47) 0.740
All-cause death 25 (2.6) 9 (1.3) 0.51 (0.24–1.08) 0.080 11 (4.5) 1.71 (0.85–3.42) 0.131
Ischemia-driven revascularization 17 (1.8) 18 (2.7) 1.50 (0.78–2.88) 0.228 3 (1.2) 0.68 (0.20–2.32) 0.543
Reinfarction—MI 9 (1.0) 16 (2.4) 2.51 (1.12–5.65) 0.026 2 (0.8) 0.86 (0.19–3.97) 0.849
Deﬁnite ST 6 (0.6) 15 (2.2) 3.53 (1.38–9.06) 0.009 1 (0.4) 0.65 (0.08–5.35) 0.686
Acute, #24 h 2 (0.2) 11 (1.6) 7.77 (1.73–34.96) 0.008 1 (0.4) 1.94 (0.18–21.31) 0.588
Subacute, >24 h to 30 days 4 (0.4) 4 (0.6) 1.41 (0.35–5.63) 0.620 0 (0.0) N/A N/A
Protocol major bleeding 57 (6.0) 16 (2.4) 0.40 (0.23–0.68) 0.0009 7 (2.9) 0.48 (0.22–1.03) 0.060
Protocol minor bleeding 74 (7.8) 36 (5.4) 0.69 (0.47–1.01) 0.057 11 (4.5) 0.58 (0.31–1.07) 0.081
MACE—death, MI, IDR, or stroke 48 (5.1) 32 (4.8) 0.94 (0.61–1.46) 0.789 17 (7.0) 1.37 (0.81–2.35) 0.244
NACE—death, MI, IDR, stroke,
or non-CABG major bleeding
97 (10.2) 43 (6.4) 0.63 (0.44–0.88) 0.008 23 (9.4) 0.92 (0.60–1.42) 0.706
Values are n (%) unless otherwise speciﬁed. *Data are not available regarding a post-PCI infusion for 35 patients. †The RR and p values are for the comparison of heparin with
optional GPI versus bivalirudin with prolonged low-dose infusion. ‡The RR and p values are for comparison of heparin with optional GPI versus bivalirudin with prolonged PCI
dose infusion.
CI ¼ conﬁdence interval; GPI ¼ glycoprotein IIb/IIIa inhibitor; IDR ¼ ischemia-driven revascularization; MACE ¼ major adverse cardiac events; MI ¼ myocardial infarction;
N/A ¼ not applicable; NACE ¼ net adverse clinical events; RR ¼ relative risk; other abbreviations as in Table 1.
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219pPCI. Importantly, EUROMAX conﬁrmed that the risk
period for AST appears to be limited to the ﬁrst few
hours after pPCI despite the fact that the Academic
Research Consortium deﬁnition encompasses the ﬁrst
24 h.
There were 2 distinct treatment strategies incor-
porated in the EUROMAX trial that had the potential
to mitigate the risk of excess AST, namely, the
extended infusion of bivalirudin and the use of the
newer P2Y12 inhibitors. According to the results of
this analysis, neither the use of prasugrel or tica-
grelor, nor a prolonged low-dose bivalirudin infusion
were able to reduce the AST risk. However, this post-
hoc analysis suggests that the selection of the full PCI
dose for the prolonged post-procedural infusion may
be associated with an AST risk that is comparable to
that observed with heparin  GPI. The higher infusion
dose did not seem to increase the risk for bleeding,
because major bleeding rates did not appear to be
substantially different between the 2 infusion doses.
As stated previously, both the choice for the use of
GPI and the selection of the dose for the prolonged
bivalirudin infusion were not randomized, but rather
left to the investigator’s discretion and almost
certainly inﬂuenced by the patient’s clinical and
procedural risk proﬁle. In that regard, the results of
this post-hoc analysis need to be interpreted with
caution especially as it relates to the overall 30-day
clinical outcomes that may be more directly related
to patient and procedural factors rather than being
indicative of treatment strategy performance.Consistent with increasing adoption of the new
P2Y12 inhibitors in contemporary practice, approxi-
mately 50% of patients in EUROMAX were treated
upstream with a loading dose of prasugrel or tica-
grelor. However, our analysis found no inﬂuence of the
choice of P2Y12 inhibitor on the rates of AST. This
observation is consistent with the pivotal trials for
both agents that did not demonstrate signiﬁcant re-
ductions in the rates of AST compared with clopidog-
rel, but did indeed reduce the risk for subacute (>24 h
and up to 30 days) ST (16,17). A plausible explanation
for the inability of even the newer agents to prevent
AST was provided by a recent study by Alexopoulos
et al. (22), which demonstrated that onset of the ex-
pected platelet inhibition with prasugrel and tica-
grelor can be delayed for up to 4 to 6 h in STEMI
patients. With the vulnerable window for AST limited
to the ﬁrst few hours after pPCI, this delayed bio-
availability of all the oral agents becomes important if
bivalirudin is stopped immediately at the end of the
procedure. The present analysis from EUROMAX sug-
gests that this vulnerable periodmay be coveredwith a
prolonged bivalirudin infusion at the PCI dose. This
post-hoc observation needs prospective conﬁrmation.
STUDY LIMITATIONS. The modeling used to deter-
mine the independent predictors of ST in this post-hoc
analysis has several limitations. The rate of AST was
extremely low at 0.6% (n ¼ 14), therefore the ability to
reliably discern predictors is limited. The model using
Firth penalized maximum likelihood estimation may
be a better-suited option when modeling rare events;
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220however, the model is still not ideal. The list of vari-
ables in the regression model was selected post-hoc,
and it is not certain that all variables that could
be associated with AST were identiﬁed. Only 27%
(n ¼ 244) of bivalirudin patients received the
BIV-PCI infusion dose post-procedure. Given this
post-randomization analysis, the ﬁndings should be
considered with caution and as hypothesis generating.
CONCLUSIONS
This analysis from EUROMAX conﬁrms that the risk
for AST is limited to the ﬁrst few hours after pPCI andthat neither the new oral P2Y12 inhibitors (prasugrel
or ticagrelor) nor a low-dose (0.25 mg/kg/h) bivalir-
udin infusion are protective. However, prolonging
the bivalirudin infusion at the full PCI dose for the
ﬁrst few hours after pPCI was not associated with a
higher risk of AST while maintaining the lower
bleeding rates, suggesting that this strategy could
potentially further optimize outcomes in pPCI.
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